Replies to post #7682 on FDA Plays

[pcrutch]

i commented on the story. people are so easily confused about the difference between Horizant and DM-1796. something had to be said. they are very different and one is going thru the 505(b)(2) route, which is MUCH LESS risky.

"Well I am glad you cut the crap on the XNPT-Horizant issue. DM-1796 will be approved in January and it should be a commercial success. Management has their act together."


Jason Napodano, CFA, tweeted the following:

"Just got an email from someone at MRK asking about sales potential for $DEPO/ABTs DM-1796 (PHN). Maybe they are interested in ex-US rights?"